-
On June 11, Kelun-Biotech announced that its independently developed TROP2 ADC drug sac-TMT (佳泰莱), in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱”), has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Med...Read more »
-
On May 29, the National Medical Products Administration (NMPA) approved the marketing of Zanidatamab, submitted by BeiGene, for the treatment of patients with unresectable locally advanced or metastatic biliary tract cancer (BTC) who have previously received systemic therapy and exhibit high HER2...Read more »
-
On Jun 04, 2025，Akeso announce that the National Medical Products Administration (NMPA) has approved the company’s first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of persistent, recurrent, or metastatic cervical cancer, in combination with platinu...Read more »
-
On May 29, the National Medical Products Administration (NMPA) approved the HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) for marketing. It is indicated as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic non-small ...Read more »
-
On May 21, 2025，InnoCare Pharma announced that the China National Medical Products Administration (NMPA) has granted approval for Minjuvi® (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide, followed by Minjuvi monotherapy, for t...Read more »
-
On May 22, 2025，Allist Pharmaceuticals announced that its innovative drug Airuikai (Glecirasib Citrate Tablets), a KRAS-G12C inhibitor, has been officially approved for market launch by the National Medical Products Administration (NMPA). The approval allows Airuikai to be used for the treatment...Read more »
-
On May 22, 2025, Kelun Bio announced that the application for a new indication of its trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK – 2870) (®) had been accepted by the Center for Drug Evaluation (...Read more »
-
In the Long – standing Battle against Cancer, New Anti – cancer Weapons Emerge Continuously, Bringing New Hope to Patients In the protracted war between humans and cancer, new anti – cancer weapons are emerging one after another, bringing new hope to patients. As a shining new s...Read more »
-
In 2021, a 67 – year – old pancreatic cancer patient created a medical miracle. After experiencing surgery, multiple rounds of chemotherapy, and the failure of TIL therapy, the clinical trial of TCR-T cell therapy she participated in made the lung metastases shrink by 72% within 6 mon...Read more »
-
On May 12, 2025, CARsgen announces preliminary clinical data for CT0596, an allogeneic BCMA-targeted CAR-T developed using the THANK-u Plus™ platform. CT0596 is currently being evaluated in an early exploratory clinical study for relapsed/refractory multiple myeloma (R/R MM) or relapsed/refractor...Read more »
-
On May 9, 2025, Hansoh Pharmaceutical announced that a new indication for Ameile (almonertinib mesylate tablets) has been approved for marketing. The new indication is for the adjuvant treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor re...Read more »
-
On May 1,2025,Hansoh Pharmaceutical announces that the Group’s self-developed B7-H4-targeted antibody-drug conjugate (ADC) HS-20089 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (NMPA) of China, wi...Read more »
Cooperative medical institution of
Beijing Cancer Hospital